Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ametumumab plus FOLFIRI in first-line RAS wild-type metastatic colorectal cancer
CTR20181002Phase 2Active
- Sponsor
- Shanghai Sailon Biotechnology
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ametumumab in colorectal adenocarcinoma, colon adenocarcinoma, rectal adenocarcinoma, sponsored by Shanghai Sailon Biotechnology. Started Jul 2018; status: active.
02
Drugs
ametumumab
03
Conditions
colorectal adenocarcinomacolon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on CTR20181002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181002.